Blockers of the delayed-rectifier potassium current in pancreatic beta-cells enhance glucose-dependent insulin secretion |
| |
Authors: | Herrington James Zhou Yun-Ping Bugianesi Randal M Dulski Paula M Feng Yue Warren Vivien A Smith McHardy M Kohler Martin G Garsky Victor M Sanchez Manuel Wagner Michael Raphaelli Kristin Banerjee Priya Ahaghotu Chinweze Wunderler Denise Priest Birgit T Mehl John T Garcia Maria L McManus Owen B Kaczorowski Gregory J Slaughter Robert S |
| |
Affiliation: | Department of Ion Channels, Merck Research Laboratories, RY80N-C31, P.O. Box 2000, Rahway, NJ 07065-0900, USA. james_herrington@merck.com |
| |
Abstract: | Delayed-rectifier K+ currents (I(DR)) in pancreatic beta-cells are thought to contribute to action potential repolarization and thereby modulate insulin secretion. The voltage-gated K+ channel, K(V)2.1, is expressed in beta-cells, and the biophysical characteristics of heterologously expressed channels are similar to those of I(DR) in rodent beta-cells. A novel peptidyl inhibitor of K(V)2.1/K(V)2.2 channels, guangxitoxin (GxTX)-1 (half-maximal concentration approximately 1 nmol/l), has been purified, characterized, and used to probe the contribution of these channels to beta-cell physiology. In mouse beta-cells, GxTX-1 inhibits 90% of I(DR) and, as for K(V)2.1, shifts the voltage dependence of channel activation to more depolarized potentials, a characteristic of gating-modifier peptides. GxTX-1 broadens the beta-cell action potential, enhances glucose-stimulated intracellular calcium oscillations, and enhances insulin secretion from mouse pancreatic islets in a glucose-dependent manner. These data point to a mechanism for specific enhancement of glucose-dependent insulin secretion by applying blockers of the beta-cell I(DR), which may provide advantages over currently used therapies for the treatment of type 2 diabetes. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|